Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | ESR1 | P03372 | 3/20 | 0.44 |
| ▸ | AURKA | O14965 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4623912 | 0.78 | METAP2 (0.35) | KDM4EMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL6489268 | 0.76 | BCHE (0.40) | RAB9AKDM4EMAPTALDH1A1HPGD | |
| SCHEMBL5051826 | 0.76 | KDR (0.68) | RAB9AKDM4EMAPTMEN1KMT2A | |
| SCHEMBL7081757 | 0.75 | APP (0.41) | CYP19A1BRD4CREBBP | |
| SCHEMBL1404094 | 0.75 | RAB9A (0.45) | RAB9AKDM4EMAPTMEN1KMT2A | |
| SCHEMBL26053434 | 0.75 | ITK (0.60) | RAB9AKDM4EMAPTMEN1KMT2A | |
| SCHEMBL10176240 | 0.75 | KDR (0.61) | RAB9AKDM4EMAPTMEN1KMT2A | |
| Benzene SCHEMBL27629233 | 0.74 | RAB9A (0.69) | RAB9AKDM4EMAPTMEN1KMT2A | |
| Methane SCHEMBL28704887 | 0.74 | KDR (0.66) | RAB9AKDM4EMAPTMEN1KMT2A | |
| SCHEMBL6746143 | 0.74 | NPC1 (0.55) | RAB9AKDM4EMAPTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4834663-B2 | — | — | 2011-12-14 | — | — | JP | claimed |
| US-7429604-B2 | Six-membered heterocycles useful as serine protease inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-09-30 | — | — | US | claimed |
| JP-2008502692-A | — | — | 2008-01-31 | — | — | JP | claimed |
| EP-1773775-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-04-18 | — | — | EP | claimed |
| US-20060009455-A1 | especially blood coagulation factor XIa and plasma kallikrein; e.g. 4-aminomethyl-[2-phenyl-1-(4-phenyl-pyridin-2-yl)-ethyl]-trans cyclohexanecarboxamide; anticoagulant, antiinflammatory agent; | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-12 | — | — | US | claimed |
| WO-2005123680-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-29 | — | — | WO | claimed |
| EP-0772600-A1 | 1,2-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-05-14 | — | — | EP | claimed |
| US-5616601-A | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation | GD SEARLE & CO (US) | 1997-04-01 | — | — | US | claimed |
| WO-1996003388-A1 | 1,2-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-02-08 | — | — | WO | claimed |
| EP-0001769-A1 | Sulfur-containing esters of 1,4-dihydropyridine carboxylic acids, their preparation and pharmaceutical use | BAYER AG (DE) | 1979-05-16 | — | — | EP | claimed |
| US-20200113830-A1 | PEGYLATED LIPOSOMES FOR DELIVERY OF IMMUNOGEN-ENCODING RNA | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2020-04-16 | — | — | US | disclosed |
| US-10202400-B2 | Cortistatin analogues and syntheses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2019-02-12 | — | — | US | disclosed |
| EP-3271015-A1 | NK-3 RECEPTOR ANTAGONISTS FOR THERAPEUTIC OR COSMETIC TREATMENT OF EXCESS BODY FAT | OGEDA S.A. (BE) | 2018-01-24 | — | — | EP | disclosed |
| US-20170320886-A1 | CORTISTATIN ANALOGUES AND SYNTHESES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-11-09 | — | — | US | disclosed |
| US-9714255-B2 | Cortistatin analogues and syntheses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-07-25 | — | — | US | disclosed |
| EP-0772600-A1 | 1,2-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-05-14 | — | — | EP | disclosed |
| US-5616601-A | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation | GD SEARLE & CO (US) | 1997-04-01 | — | — | US | disclosed |
| WO-1996003388-A1 | 1,2-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-02-08 | — | — | WO | disclosed |
| EP-0302793-A2 | Aralkylaminoalkoxyphenyl derivatives, process of preparation and compositions containing the same | ELF SANOFI (FR) | 1989-02-08 | — | — | EP | disclosed |
| EP-0001769-A1 | Sulfur-containing esters of 1,4-dihydropyridine carboxylic acids, their preparation and pharmaceutical use | BAYER AG (DE) | 1979-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009455-A1 | especially blood coagulation factor XIa and plasma kallikrein; e.g. 4-aminomethyl-[2-phenyl-1-(4-phenyl-pyridin-2-yl)-ethyl]-trans cyclohexanecarboxamide; anticoagulant, antiinflammatory agent; | F12, F11, F2 | RAB9A 2816/4885KDM4E 247/4885MAPT 4095/4885 |
| US-20200113830-A1 | PEGYLATED LIPOSOMES FOR DELIVERY OF IMMUNOGEN-ENCODING RNA | LY96, EXOSC5, EXOSC4 | RAB9A 1163/4885KDM4E 1854/4885MAPT 2697/4885 |
| US-10202400-B2 | Cortistatin analogues and syntheses thereof | CTTN, TEK, FLT1 | RAB9A 968/4885KDM4E 3276/4885MAPT 3439/4885 |
| US-20170320886-A1 | CORTISTATIN ANALOGUES AND SYNTHESES THEREOF | CTTN, TEK, FLT1 | RAB9A 968/4885KDM4E 3276/4885MAPT 3439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.